PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmAla Biotech Holdings Inc. has partnered with the University of Texas, San Antonio, to supply a unique dosage form of their proprietary LaNeo™ MDMA for a clinical trial. Additionally, the company has announced the publication of a patent application for APA-01, a new molecular entity, signaling growth in their intellectual property portfolio.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.